

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 14 of 14 returned.

☐ 1. Document ID: [US 20040096491 A1](#)

Using default format because multiple data bases are involved.

L9: Entry 1 of 14

File: PGPB

May 20, 2004

PGPUB-DOCUMENT-NUMBER: 20040096491

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: [US 20040096491 A1](#)

TITLE: Adhesive patch

PUBLICATION-DATE: May 20, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Tateishi, Tetsuro	Tsukuba-shi		JP	
Terahara, Takaaki	Tsukuba-shi		JP	
Higo, Naruhito	Tsukuba-shi		JP	

US-CL-CURRENT: [424/449](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw Da
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	---------

☐ 2. Document ID: [US 20040057987 A1](#)

L9: Entry 2 of 14

File: PGPB

Mar 25, 2004

PGPUB-DOCUMENT-NUMBER: 20040057987

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: [US 20040057987 A1](#)

TITLE: Novel formulations for the transdermal administration of fenoldopam

PUBLICATION-DATE: March 25, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
van Osdol, William W.	Mountain View	CA	US	
Crisologo, Nieves M.	Sunnyvale	CA	US	
Yum, Su Il	Los Altos	CA	US	

US-CL-CURRENT: [424/449](#); [514/217.02](#)

ABSTRACT:

Composition of matter for application to a body surface or membrane to administer fenoldopam by permeation through the body surface or membrane, the composition comprising fenoldopam to be administered, at a therapeutically effective rate, in combination with a permeation enhancer or mixture. Also disclosed are drug delivery devices and methods for the transdermal administration of fenoldopam for the treatment of hypertension, congestive heart failure, and chronic and acute renal failure.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMC	Draw De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	---------

☐ 3. Document ID: US 20030198662 A1

L9: Entry 3 of 14

File: PGPB

Oct 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030198662

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030198662 A1

TITLE: Transdermal administration of N-(2,5-disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methyl guanidines

PUBLICATION-DATE: October 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Van Osdol, William Woodson	Mountain View	CA	US	
Gale, Robert Martin	Los Altos	CA	US	
Brandwein, David Henry	New Brighton	MN	US	
Padmanabhan, Rama	Los Altos	CA	US	
Sunram, Joan	Coon Rapids	MN	US	

US-CL-CURRENT: 424/449; 514/634

ABSTRACT:

Composition of matter for application to a body surface or membrane to administer a N-(2,5-Disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methyl guanidine by permeation through the body surface or membrane, the composition comprising the guanidine compound to be administered, at a therapeutically effective rate, optionally in combination with a permeation enhancer or mixture. Also disclosed are drug delivery devices and methods for the transdermal administration of a guanidine for the prevention of neuropathic pain, neuropsychological deficits resulting from cardiac surgery (CABG), and other neurological disorders.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMC	Draw De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	---------

☐ 4. Document ID: US 20030166624 A1

L9: Entry 4 of 14

File: PGPB

Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166624
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030166624 A1

TITLE: Novel formulations for the administration of fluoxetine

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gale, Robert M.	Los Altos	CA	US	
Nelson, Melinda K.	Sunnyvale	CA	US	
Cormier, Michel J.N.	Mountain View	CA	US	
Gupta, Suneel K.	Sunnyvale	CA	US	
Campbell, Patricia S.	Palo Alto	CA	US	

US-CL-CURRENT: 514/171; 514/651

ABSTRACT:

Composition of matter for application to a body surface or membrane to administer fluoxetine by permeation through the body surface or membrane, the composition comprising fluoxetine to be administered, at a therapeutically effective rate, alone or in combination with a permeation enhancer or mixture. A preferred embodiment is directed to the transdermal administration of fluoxetine at reduced skin irritation levels wherein fluoxetine, preferably provided as fluoxetine acetate, is coadministered with a corticosteroid such as hydrocortisone. Also disclosed are drug delivery devices containing the fluoxetine or fluoxetine and enhancer composition and methods for the transdermal administration of the fluoxetine and fluoxetine/enhancer composition.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMD	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	--------

☐ 5. Document ID: US 20030108609 A1

L9: Entry 5 of 14

File: PGPB

Jun 12, 2003

PGPUB-DOCUMENT-NUMBER: 20030108609
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030108609 A1

TITLE: Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles

PUBLICATION-DATE: June 12, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Berry, Stephen A.	Hollister	CA	US	

Fereira, Pamela J.	Redwood City	CA	US
Dehnad, Houdin	El Granada	CA	US
Muchnik, Anna	Belmont	CA	US

US-CL-CURRENT: 424/486

ABSTRACT:

This invention relates to stable non-aqueous single phase viscous vehicles and to formulations utilizing such vehicles. The formulations comprise at least one beneficial agent uniformly suspended in the vehicle. The formulation is capable of being stored at temperatures ranging from cold to body temperature for long periods of time. The formulations are capable of being uniformly delivered from drug delivery systems at an exit shear rate of between about 1 to 1.times.10.sup.-7 reciprocal second.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 6. Document ID: US 20030082122 A1

L9: Entry 6 of 14

File: PGPB

May 1, 2003

PGPUB-DOCUMENT-NUMBER: 20030082122

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030082122 A1

TITLE: Titanium dioxide particles

PUBLICATION-DATE: May 1, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Chopin, Thierry	Saint-Leu-la-Forêt		FR	
Dupuis, Dominique	Deuil-la-Barre		FR	
Willemin, Claudie	Paris		FR	

US-CL-CURRENT: 424/63; 106/436

ABSTRACT:

Anatase titanium dioxide particles no larger than 100 nm and coated with a layer of a metal oxide, hydroxide or oxhydroxide, said particles having a BET specific surface area of at least 70 m.sup.2/g and a density of around 2.2. A method for preparing said particles, and the use thereof as an anti-UV agent, in particular for preparing formulations for cosmetics, varnishes, paints and plastics, are also disclosed.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 7. Document ID: US 20010051182 A1

L9: Entry 7 of 14

File: PGPB

Dec 13, 2001

PGPUB-DOCUMENT-NUMBER: 20010051182
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010051182 A1

TITLE: Skin patch for use in contact immunotherapy

PUBLICATION-DATE: December 13, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hopp, Robert B.	Richland	WA	US	

US-CL-CURRENT: 424/449; 424/195.18, 424/275.1

ABSTRACT:

A device, preferably in the form of a skin patch, is disclosed for usage in the delivery of a contactant to human skin for the purpose of treating medical conditions responsive to contact immunotherapy, without the presence of medication to alleviate contact dermatitis induced by the contactant. The skin patch specifically induces a cell-mediated contact dermatitis in the treatment of skin disorders. Its anticipated use pertains to treatment of, for example, human papilloma virus infections, or warts. In a first embodiment, a pressure activated single chambered skin patch is topically applied and used for controlled release of contactant to human skin. In a second embodiment, a pressure activated two-chambered skin patch is topically applied and used for controlled release of a contactant to human skin. Alternatively, a single chambered skin patch is topically applied and hydrated by the contacted skin for release of contactant. In an additional embodiment, the contactant may be applied separately of the skin patch portion, in a manner that maintains the contactant in contact with the patient's skin for the predetermined period of time necessary to cause sufficient contact dermatitis to effect resolution of the medical condition.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMC	Draw De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	---------

☐ 8. Document ID: US 20030166624 A1

L9: Entry 8 of 14

File: DWPI

Sep 4, 2003

DERWENT-ACC-NO: 2004-119126
DERWENT-WEEK: 200464
COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Sustained release composition useful for treating, e.g. depression or sexual dysfunction, comprises fluoxetine salt and a carrier

INVENTOR: CAMPBELL, P S; CORMIER, M J N ; GALE, R M ; GUPTA, S K ; NELSON, M K

PRIORITY-DATA: 2002US-0302490 (November 22, 2002), 1996US-021727P (July 15, 1996),

1997US-038425P (February 19, 1997), 1997US-0892118 (July 14, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20030166624 A1	September 4, 2003		021	A61K031/573

INT-CL (IPC): A61 K 31/137; A61 K 31/573

ABSTRACTED-PUB-NO: US20030166624A

BASIC-ABSTRACT:

NOVELTY - A sustained release composition comprises fluoxetine salt and a carrier. The fluoxetine is released at the rate of 250-3200 micro g/hr during an administration for at least 12 hours to achieve and maintain blood or plasma levels throughout administration period.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) a device (D1) for the transdermal administration of fluoxetine comprising:

(a) a reservoir (a1) containing salt of fluoxetine;

(b) a backing (b2) behind the body contacting distal surface of (a1); and

(c) device (c1) for maintaining (a1) in fluoxetine transmitting relation with a body surface or membrane. The device has a surface area defining an area of fluoxetine delivery of less than 60 cm²;

(2) a device (D2) for the transdermal administration of fluoxetine comprises:

(a) a first reservoir (a2) containing fluoxetine,

(b) a second reservoir (b2) containing an excess of fluoxetine salt at or below saturation when in equilibrium with (a2),

(c) a rate-controlling membrane (c2) between the (a2) and (b2),

(d) a backing (d2) behind the body contacting-distal surface of the second reservoir, and

(e) device (e2) for maintaining (a2) and (b2) in fluoxetine-transmitting relation with a body surface or membrane; and

(3) transdermal administration of a drug having a half-life of greater than 24 hours involving:

(a) administering the drug to an area of skin in a carrier to permit sustained release of the drug at a rate through the skin during a first predetermined period of time to provide blood or plasma levels of the drug;

(b) removing the drug and carrier from the area of skin for a second predetermined period of time of at least 20 hours where no additional drug is applied to the skin during the second predetermined time period;

(c) repeating steps (a) and (b) for as long as drug therapy is desired, where blood or plasma levels of the drug are achieved during the first predetermined time period and maintained during the second predetermined period and continued.

ACTIVITY - Antidepressant; Endocrine-Gen.

No biological data given.

MECHANISM OF ACTION - None given.

USE - The composition is used for sustained release of drug (e.g. fluoxetine, norfluoxetine) (claimed) useful for treating depression, sexual dysfunction, avoiding unwanted adverse toxic or psychological effects.

ADVANTAGE - The fluoxetine is released at the rate of 250-3200 (preferably 400-1200) micro g/hr during an administration for at least 12 hours to achieve and maintain blood or plasma levels throughout administration.

The composition is safe and has reduced skin irritation levels.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	Summary	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	---------	----------

9. Document ID: CN 1499962 A, WO 200269942 A1, EP 1366762 A1, KR 2003080070 A, BR 200207955 A, AU 2002236252 A1, US 20040096491 A1, JP 2002569120 X

L9: Entry 9 of 14

File: DWPI

May 26, 2004

DERWENT-ACC-NO: 2002-732771

DERWENT-WEEK: 200458

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Adhesive patch for administering drugs contains acrylic polymer containing no carboxyl or hydroxyl groups and a rubbery polymer as pressure sensitive adhesive base

INVENTOR: HIGO, N; TATEISHI, T ; TERAHARA, T

PRIORITY-DATA: 2001JP-0063767 (March 7, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>CN 1499962 A</u>	May 26, 2004		000	A61K009/70
<u>WO 200269942 A1</u>	September 12, 2002	J	038	A61K009/70
<u>EP 1366762 A1</u>	December 3, 2003	E	000	A61K009/70
<u>KR 2003080070 A</u>	October 10, 2003		000	A61K009/70
<u>BR 200207955 A</u>	February 25, 2004		000	A61K009/70
<u>AU 2002236252 A1</u>	September 19, 2002		000	A61K009/70
<u>US 20040096491 A1</u>	May 20, 2004		000	A61K009/70
<u>JP 2002569120 X</u>	July 2, 2004		000	A61K009/70

INT-CL (IPC): A61 K 9/70; A61 K 31/216; A61 K 31/48; A61 K 47/32; A61 P 13/00; A61 P 25/16

ABSTRACTED-PUB-NO: WO 200269942A

BASIC-ABSTRACT:

NOVELTY - Adhesive patch comprises (i) a pressure-sensitive adhesive layer comprising (a) a pressure sensitive adhesive base comprising an acrylic polymer containing no carboxyl or hydroxyl groups and a rubbery polymer; and (b) a drug; on

(ii) a substrate.

USE - As an adhesive patch for administering drugs (preferably pergolide or oxybutynin).

ADVANTAGE - Gives stable percutaneous administration at a sufficiently high level.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	Drawings	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	----------	----------

☐ 10. Document ID: US 20010051182 A1

L9: Entry 10 of 14

File: DWPI

Dec 13, 2001

DERWENT-ACC-NO: 2002-302991

DERWENT-WEEK: 200234

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Device useful in contact immunotherapy comprises a standardized dosage of a contactant that causes dermatitis e.g. dinitrochlorobenzene or nickel sulfate, a shroud enclosing the contactant and an adhesive associated with the shroud

INVENTOR: HOPP, R B

PRIORITY-DATA: 2001US-0768156 (January 25, 2001), 1996US-0717108 (September 20, 1996), 1998US-0095700 (June 8, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 20010051182 A1</u>	December 13, 2001		015	A61K039/35

INT-CL (IPC): A61 K 9/70; A61 K 39/35

ABSTRACTED-PUB-NO: US20010051182A

BASIC-ABSTRACT:

NOVELTY - A device comprises a standardized dosage of a contactant dermatitis in human skin, a shroud enclosing the contactant and an adhesive associated with the shroud for temporarily and releasably attaching the shroud to a patient such that the contactant is in contact with the skin to induce contact dermatitis.

DETAILED DESCRIPTION - A device comprises a standardized dosage of a contactant dermatitis in human skin, a shroud enclosing the contactant and an adhesive associated with the shroud for temporarily and releasably attaching the shroud to a patient such that the contactant is in contact with the skin to induce contact dermatitis.

An INDEPENDENT CLAIM is included for treating medical conditions in a patient responsive to contact immunotherapy involving (i) adhesively applying the device to the patient's skin with no medication to alleviate the contact dermatitis; (ii) maintaining the device adjacent to the skin to intentionally induce contact dermatitis and then removing the device; and reapplying additional devices containing the contactant at a predetermined interval to maintain the contact dermatitis until the medical condition is resolved.

ACTIVITY - Virucide; Anti-HIV; Anti-fungal; Cytostatic; Dermatological.

MECHANISM OF ACTION - None given.

USE - The device is useful for the topical administration of controlled quantities of the contactant that induces a contact dermatitis to a patient e.g. human suffering from medical conditions (e.g. papilloma virus, alopecia areata, vitiligo and AIDS) responsive to contact immunotherapy (claimed). Also for treating warts, treatment of other cutaneous viral infections e.g. Molluscum contagiosum, Herpes simplex, and Herpes Zoster; chronic cutaneous fungal infections such as Dermatophyte infection and mycetoma; and skin malignancies such as basal cell carcinoma, squamous cell carcinoma and melanoma.

ADVANTAGE - The delivery system includes the advantages such as standardized dosing; safety from unintended exposure to the contactant; ease of use by ancillary medical personnel; localization of the contactant to the treatment area; and stabilized storage form. It also includes provision of a dye to mark the treatment area, increased penetration of the contactant established by hydration and occlusion of the skin; and ability to use penetration enhancer in combination with the contactant to increase the permeability of the contactant. The method of application for the contactant by the device becomes standardized and reproducible, and is no longer dependent on the individual who is applying the contactant. The system will facilitate studies to determine optimum rates of release of contactant and to measure the exposure times that yield optimal treatment results.

DESCRIPTION OF DRAWING(S) - The figure shows a schematic sectional view of a skin patch i.e. a single reservoir delivery device.

shroud 10

adhesive flange 11

containment chamber 12

gel matrix 13

paper discs 14

covering rupturable membrane 15

release liner. 16

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	EMC	Draw	Doc
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	-----	------	-----

☐ 11. Document ID: US 20030198662 A1, WO 200119352 A1, AU 200075760 A, EP 1216036 A1

L9: Entry 11 of 14

File: DWPI

Oct 23, 2003

DERWENT-ACC-NO: 2001-257839

DERWENT-WEEK: 200370

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Composition for transdermal administration of guanidine compound useful for preventing neuropathic pain includes carrier to permit sustained release

INVENTOR: BRANDWEIN, D H; GALE, R M ; PADMANABHAN, R ; SUNRAM, J ; VAN OSDOL, W W

PRIORITY-DATA: 1999US-153996P (September 15, 1999), 2000US-0658649 (September 8,

2000), 2003US-0412104 (April 11, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 20030198662 A1</u>	October 23, 2003		000	A61K009/70
<u>WO 200119352 A1</u>	March 22, 2001	E	038	A61K009/70
<u>AU 200075760 A</u>	April 17, 2001		000	A61K009/70
<u>EP 1216036 A1</u>	June 26, 2002	E	000	A61K009/70

INT-CL (IPC): A61 K 9/70; A61 K 31/155

ABSTRACTED-PUB-NO: WO 200119352A

BASIC-ABSTRACT:

NOVELTY - Composition comprises an N-(2,5-disubstituted phenyl)-N'-(3-substituted-phenyl)-N'-methyl guanidine (I) or its salts in a carrier to permit sustained release of the compound.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for

a device for the transdermal administration of a therapeutic agent which comprises:

(a) a reservoir comprising an N-(2,5-disubstituted phenyl)-N'-(3-substituted-phenyl)-N'-methyl guanidine (I) or its salts;

(b) a backing behind the body distal surface of the reservoir, and

(c) means for maintaining the reservoir in therapeutic agent transmitting relation with a body surface or membrane, in which a therapeutic effective amount of guanidine is delivered at an effective rate during an administration period in order to achieve and maintain therapeutic blood or plasma levels throughout a substantial portion of the administration period.

ACTIVITY - Analgesic; neuroprotective.

MECHANISM OF ACTION - None given.

USE - Used for treatment of neuropathic pain, neuropsychological deficits resulting from cardiac surgery and other neurological disorders.

ADVANTAGE - (I) Can be safely and efficaciously administered by a sustained release formulation.

DESCRIPTION OF DRAWING(S) - The drawing shows a cross-section view of a transdermal administration device (30).

Delivery device 30

Reservoir 12

Contact adhesive layer 16

Backing 14

Removable release liner 24

Enhancer reservoir 26

Rate controlling membrane 28

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	KIMC	Draw De
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	------	---------

□ 12. Document ID: NZ 513441 A, WO 200045790 A2, AU 200034816 A, NO 200103861 A, EP 1152749 A2, KR 2001101842 A, CN 1339962 A, HU 200200202 A2, JP 2002536315 W, ZA 200106443 A, US 20030108609 A1, MX 2001008006 A1

L9: Entry 12 of 14

File: DWPI

Jan 30, 2004

DERWENT-ACC-NO: 2000-532854

DERWENT-WEEK: 200414

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Stable non-aqueous single phase viscous vehicles and formulations comprising them, for extended delivery of peptides, proteins, nucleotides, hormone, viruses or antibodies

INVENTOR: BERRY, S A; DEHNAD, H ; FEREIRA, P J ; MUCHNIK, A ; FERREIRA, P J

PRIORITY-DATA: 1999US-119170P (February 8, 1999), 2000US-0497422 (February 3, 2000), 2002US-0319277 (December 12, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>NZ 513441 A</u>	January 30, 2004		000	A61K009/10
<u>WO 200045790 A2</u>	August 10, 2000	E	042	A61K009/10
<u>AU 200034816 A</u>	August 25, 2000		000	A61K009/10
<u>NO 200103861 A</u>	September 20, 2001		000	A61K009/10
<u>EP 1152749 A2</u>	November 14, 2001	E	000	A61K009/10
<u>KR 2001101842 A</u>	November 14, 2001		000	A61K009/10
<u>CN 1339962 A</u>	March 13, 2002		000	A61K009/10
<u>HU 200200202 A2</u>	May 28, 2002		000	A61K009/10
<u>JP 2002536315 W</u>	October 29, 2002		050	A61K009/10
<u>ZA 200106443 A</u>	October 30, 2002		060	A61K000/00
<u>US 20030108609 A1</u>	June 12, 2003		000	A61K009/14
<u>MX 2001008006 A1</u>	February 1, 2002		000	A61K009/10

INT-CL (IPC): A61 K 0/00; A61 K 9/10; A61 K 9/14; A61 K 38/27; A61 K 38/51; A61 K 47/06; A61 K 47/10; A61 K 47/14; A61 K 47/22; A61 K 47/30; A61 K 47/32; A61 K 47/34; A61 P 5/10

ABSTRACTED-PUB-NO: WO 200045790A

BASIC-ABSTRACT:

NOVELTY - Suspending beneficial agents in non-aqueous single phase biocompatible viscous vehicles provides stable formulations which can be delivered at body temperature over an extended time at low flow rates.

DETAILED DESCRIPTION - A stable non-aqueous single phase biocompatible viscous vehicle capable of suspending beneficial agents and homogeneously dispensing them

over an extended time at body temperature and low flow rates.

INDEPENDENT CLAIMS are included for formulations comprising the vehicles, their preparation and uses.

USE - For treatment of conditions alleviated by the beneficial agent.

ADVANTAGE - The stability of a beneficial agent is increased by using the vehicle. For example, human growth hormone was found to be stable at 37 deg. C over 12 weeks in formulations of PVP (polyvinylpyrrolidone)/PEG (polyethylene glycol), pluronic and glycerol monolaurate/lauryl lactate/PVP.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	Excluded	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	--------	----------	----------

☐ 13. Document ID: DE 69918124 E, WO 200004886 A1, AU 9951056 A, EP 1100476 A1, JP 2002521324 W, US 6699497 B1, US 20040057987 A1, EP 1100476 B1

L9: Entry 13 of 14

File: DWPI

Jul 22, 2004

DERWENT-ACC-NO: 2000-171346

DERWENT-WEEK: 200450

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Composition for transdermal administration comprising fenoldopam and a permeation enhancer, useful for treating hypertension, congestive heart failure and particularly renal failure

INVENTOR: CRISOLOGO, N M; VAN OSDOL, W W ; YUM, S I

PRIORITY-DATA: 1998US-094059P (July 24, 1998), 1999US-0361026 (July 23, 1999), 2003US-0675715 (September 29, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>DE 69918124 E</u>	July 22, 2004		000	A61K009/70
<u>WO 200004886 A1</u>	February 3, 2000	E	041	A61K009/70
<u>AU 9951056 A</u>	February 14, 2000		000	A61K009/70
<u>EP 1100476 A1</u>	May 23, 2001	E	000	A61K009/70
<u>JP 2002521324 W</u>	July 16, 2002		053	A61K031/55
<u>US 6699497 B1</u>	March 2, 2004		000	A61F013/02
<u>US 20040057987 A1</u>	March 25, 2004		000	A61K031/55
<u>EP 1100476 B1</u>	June 16, 2004	E	000	A61K009/70

INT-CL (IPC): A61 F 13/02; A61 K 9/70; A61 K 31/55; A61 P 9/04; A61 P 9/12; A61 P 13/12

ABSTRACTED-PUB-NO: WO 200004886A

BASIC-ABSTRACT:

NOVELTY - Compositions and devices for transdermal administration of fenoldopam (I) comprises (I) and a permeation enhancer.

ACTIVITY - Hypotensive; Cardiant; Nephrotropic.

MECHANISM OF ACTION - None given.

USE - For treating hypertension, congestive heart failure and particularly renal failure.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	Form	Draw De
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	---------

☐ 14. Document ID: US 6740312 B2, WO 9730130 A1, FR 2744914 A1, AU 9718834 A, EP 880564 A1, CN 1211272 A, JP 11506155 W, BR 9707499 A, EP 880564 B1, DE 69701859 E, ES 2146083 T3, JP 3091496 B2, AU 727150 B, RU 2162443 C2, CA 2253223 C, US 20030082122 A1, IL 125779 A

L9: Entry 14 of 14

File: DWPI

May 25, 2004

DERWENT-ACC-NO: 1997-425015

DERWENT-WEEK: 200435

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Particles of anatase titanium di:oxide, useful as anti-UV agent e.g. in cosmetics, varnishes, paints and plastics - are coated with metallic oxide, hydroxide or oxo:hydroxide, and form stable dispersions without using dispersing agent

INVENTOR: CHOPIN, T; DUPUIS, D ; WILLEMIN, C

PRIORITY-DATA: 1996FR-0001850 (February 15, 1996)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 6740312 B2	May 25, 2004		000	A61K007/42
WO 9730130 A1	August 21, 1997	F	034	C09D017/00
FR 2744914 A1	August 22, 1997		031	A61K007/40
AU 9718834 A	September 2, 1997		000	C09D017/00
EP 880564 A1	December 2, 1998	F	000	C09D017/00
CN 1211272 A	March 17, 1999		000	C09D017/00
JP 11506155 W	June 2, 1999		038	C09C001/36
BR 9707499 A	July 27, 1999		000	C09D017/00
EP 880564 B1	May 3, 2000	F	000	C09D017/00
DE 69701859 E	June 8, 2000		000	C09D017/00
ES 2146083 T3	July 16, 2000		000	C09D017/00
JP 3091496 B2	September 25, 2000		017	C09C001/36
AU 727150 B	December 7, 2000		000	C09D017/00
RU 2162443 C2	January 27, 2001		000	C01G023/053
CA 2253223 C	January 8, 2002	F	000	C09C001/36
US 20030082122 A1	May 1, 2003		000	A61K007/42
IL 125779 A	September 17, 2003		000	C01G023/053

A1 , IL 125779 A INT-CL (IPC): A61 K 7/00; A61 K 7/21; A61 K 7/40; A61 K 7/42; A61 K 9/15; A61 K 9/16; C01 G 23/00; C01 G 23/047; C01 G 23/053; C08 K 3/22; C09 C 1/36; C09 D 5/32; C09 D 7/12; C09 D 17/00

ABSTRACTED-PUB-NO: EP 880564B
BASIC-ABSTRACT:

Particles of anatase titanium dioxide with a particle size of at most 100 nm are coated at least partially with a layer of at least one metallic oxide, hydroxide or oxohydroxide and have a BET specific surface of at least 70 m²/g and a density of about 2.2.

Preferably the weight ratio of the metal oxides, hydroxides or oxyhydroxides to TiO₂ is at most 60 wt.%. The TiO₂ is preferably coated with a layer of silica or a hydroxide or oxohydroxide of aluminium in simple or mixed form. A preferable coating layer is of silica and of aluminium hydroxide or oxohydroxide in an amount of 15 wt.% SiO₂ and 5% Al₂O₃ w.r.t. TiO₂.

USE - The product is especially useful as an anti-UV agent in the formulation of cosmetics, varnishes, paints and plastics.

ADVANTAGE - The particles form stable dispersions without the use of a dispersing agent.

ABSTRACTED-PUB-NO:

WO 9730130A EQUIVALENT-ABSTRACTS:

Particles of anatase titanium dioxide with a particle size of at most 100 nm are coated at least partially with a layer of at least one metallic oxide, hydroxide or oxohydroxide and have a BET specific surface of at least 70 m²/g and a density of about 2.2.

Preferably the weight ratio of the metal oxides, hydroxides or oxyhydroxides to TiO₂ is at most 60 wt.%. The TiO₂ is preferably coated with a layer of silica or a hydroxide or oxohydroxide of aluminium in simple or mixed form. A preferable coating layer is of silica and of aluminium hydroxide or oxohydroxide in an amount of 15 wt.% SiO₂ and 5% Al₂O₃ w.r.t. TiO₂.

USE - The product is especially useful as an anti-UV agent in the formulation of cosmetics, varnishes, paints and plastics.

ADVANTAGE - The particles form stable dispersions without the use of a dispersing agent.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	EMC	Draw. De
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	-----	----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Term	Documents
US-20040096491\$	0
US-20040096491-A1	2
US-20040057987\$	0
US-20040057987-A1	2
US-20030198662\$	0
US-20030198662-A1	2
US-20030166624\$	0

US-20030166624-A1	2
US-20030108609\$	0
US-20030108609-A1	2
(US-20040096491\$.DID. OR US-20040057987\$.DID. OR US-20030198662\$.DID. OR US-20030166624\$.DID. OR US-20030108609\$.DID. OR US-20030082122\$.DID. OR US-20010051182\$.DID.).PGPB,USPT,USOC,EPAB,JPAB,DWPI.	14

[There are more results than shown above. Click here to view the entire set.](#)

Display Format: [Change Format](#)

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

WEST Search History

DATE: Monday, October 25, 2004

Hide?	<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L14	L13 and L8	12
<input type="checkbox"/>	L13	L9 and L11 and L12	17
<input type="checkbox"/>	L12	lauryl lactate	746
<input type="checkbox"/>	L11	glycerol monolaurate	1121
<input type="checkbox"/>	L10	L9 and L8	13
<input type="checkbox"/>	L9	polysorbate or polyvinylpyrrolidone	69984
<input type="checkbox"/>	L8	L7 or L3	40
<input type="checkbox"/>	L7	US-20040096491\$.did. or US-20040057987\$.did. or US-20030198662\$.did. or US-20030166624\$.did. or US-20030108609\$.did. or US-20030082122\$.did. or US-20010051182\$.did.	14
<input type="checkbox"/>	L6	L5 and higo.inv.	10
<input type="checkbox"/>	L5	(adhesive adj patch).ti.	229
<input type="checkbox"/>	L4	Tateishi.in.	4778
<input type="checkbox"/>	L3	US-2004096491\$.did. or US-2004057987\$.did. or 6699497.pn. or US-2003198662\$.did. or US-2003166624\$.did. or US-2003108609\$.did. or US-2003082122\$.did. or 6740312.pn. or 6517866.pn. or 6512010.pn. or 6417227.pn. or 6365178.pn. or US-2001051182\$.did. or 6267984.pn. or 6203817.pn. or 6187438.pn. or 6004578.pn. or 5928666.pn. or 5912009.pn. or 5814323.pn. or 5843468.pn.	28
		<i>DB=USPT; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L2	US-2004096491\$.did. or US-2004057987\$.did. or 6699497.pn. or US-2003198662\$.did. or US-2003166624\$.did. or US-2003108609\$.did. or US-2003082122\$.did. or 6740312.pn. or 6517866.pn. or 6512010.pn. or 6417227.pn. or 6365178.pn. or US-2001051182\$.did. or 6267984.pn. or 6203817.pn. or 6187438.pn. or 6004578.pn. or 5928666.pn. or 5912009.pn. or 5814323.pn. or 5843468.pn.	13
<input type="checkbox"/>	L1	6004578.pn.	1

END OF SEARCH HISTORY

09/497,422

L5 ANSWER 1 OF 24 USPATFULL on STN

ACCESSION NUMBER: 2004:126512 USPATFULL

TITLE: Adhesive patch

INVENTOR(S): Tateishi, Tetsuro, Tsukuba-shi, JAPAN
Terahara, Takaaki, Tsukuba-shi, JAPAN
Higo, Naruhito, Tsukuba-shi, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004096491	A1	20040520
APPLICATION INFO.:	US 2003-469612	A1	20030904 (10)
	WO 2002-JP2142		20020307

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2001-63767	20010307
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FITCH EVEN TABIN AND FLANNERY, 120 SOUTH LA SALLE STREET, SUITE 1600, CHICAGO, IL, 60603-3406	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1111	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A patch agent of the present invention comprises a support, and an adhesive layer laid on the support and containing an adhesive base and a drug, wherein the adhesive base contains an acrylic polymer substantially having no carboxyl and no hydroxyl in molecules thereof, and a rubber-based polymer, so as to achieve sufficiently high skin permeability of the drug and preparation properties. Accordingly, the present invention enables administration of the drug through skin to be implemented with drug administration effect at a sufficiently high level and on a stable basis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 24 USPATFULL on STN

ACCESSION NUMBER: 2004:76209 USPATFULL

TITLE: Novel formulations for the transdermal administration of fenoldopam

INVENTOR(S): van Osdol, William W., Mountain View, CA, UNITED STATES
Crisologo, Nieves M., Sunnyvale, CA, UNITED STATES
Yum, Su Il, Los Altos, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004057987	A1	20040325
APPLICATION INFO.:	US 2003-675715	A1	20030929 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-361026, filed on 23 Jul 1999, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-94059P	19980724 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003	

blessing

09/497,422

NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 1028

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Composition of matter for application to a body surface or membrane to administer fenoldopam by permeation through the body surface or membrane, the composition comprising fenoldopam to be administered, at a therapeutically effective rate, in combination with a permeation enhancer or mixture. Also disclosed are drug delivery devices and methods for the transdermal administration of fenoldopam for the treatment of hypertension, congestive heart failure, and chronic and acute renal failure.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 24 USPATFULL on STN

ACCESSION NUMBER: 2004:53248 USPATFULL

TITLE: Formulations for the transdermal administration of fenoldopam

INVENTOR(S): van Osdol, William W., Mountain View, CA, United States
Crisologo, Nieves M., Sunnyvale, CA, United States
Yum, Su Il, Los Altos, CA, United States

PATENT ASSIGNEE(S): Alza Corporation, Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6699497	B1	20040302
APPLICATION INFO.:	US 1999-361026		19990723 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-94059P	19980724 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Dodson, Shelley A.	
LEGAL REPRESENTATIVE:	Date, Vandana	
NUMBER OF CLAIMS:	34	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Figure(s); 6 Drawing Page(s)	
LINE COUNT:	1000	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Composition of matter for application to a body surface or membrane to administer fenoldopam by permeation through the body surface or membrane, the composition comprising fenoldopam to be administered, at a therapeutically effective rate, in combination with a permeation enhancer or mixture. Also disclosed are drug delivery devices and methods for the transdermal administration of fenoldopam for the treatment of hypertension, congestive heart failure, and chronic and acute renal failure.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 24 USPATFULL on STN

ACCESSION NUMBER: 2003:282321 USPATFULL

TITLE: Transdermal administration of N-(2,5-disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methyl guanidines

INVENTOR(S): Van Osdol, William Woodson, Mountain View, CA, UNITED

blessing

STATES

Gale, Robert Martin, Los Altos, CA, UNITED STATES
 Brandwein, David Henry, New Brighton, MN, UNITED STATES
 Padmanabhan, Rama, Los Altos, CA, UNITED STATES
 Sunram, Joan, Coon Rapids, MN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003198662	A1	20031023
APPLICATION INFO.:	US 2003-412104	A1	20030411 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-658649, filed on 8 Sep 2000, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-153996P	19990915 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	1038	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB Composition of matter for application to a body surface or membrane to administer a N-(2,5-Disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methyl guanidine by permeation through the body surface or membrane, the composition comprising the guanidine compound to be administered, at a therapeutically effective rate, optionally in combination with a permeation enhancer or mixture. Also disclosed are drug delivery devices and methods for the transdermal administration of a guanidine for the prevention of neuropathic pain, neuropsychological deficits resulting from cardiac surgery (CABG), and other neurological disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 24 USPATFULL on STN

ACCESSION NUMBER: 2003:238466 USPATFULL
 TITLE: Novel formulations for the administration of fluoxetine
 INVENTOR(S): Gale, Robert M., Los Altos, CA, UNITED STATES
 Nelson, Melinda K., Sunnyvale, CA, UNITED STATES
 Cormier, Michel J.N., Mountain View, CA, UNITED STATES
 Gupta, Suneel K., Sunnyvale, CA, UNITED STATES
 Campbell, Patricia S., Palo Alto, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003166624	A1	20030904
APPLICATION INFO.:	US 2002-302490	A1	20021122 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-892118, filed on 14 Jul 1997, GRANTED, Pat. No. US 6512010		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-21727P	19960715 (60)
	US 1997-38425P	19970219 (60)
DOCUMENT TYPE:	Utility	

09/497,422

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ALZA CORPORATION, P O BOX 7210, INTELLECTUAL PROPERTY
DEPARTMENT, MOUNTAIN VIEW, CA, 940397210

NUMBER OF CLAIMS: 47
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 1330

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Composition of matter for application to a body surface or membrane to administer fluoxetine by permeation through the body surface or membrane, the composition comprising fluoxetine to be administered, at a therapeutically effective rate, alone or in combination with a permeation enhancer or mixture. A preferred embodiment is directed to the transdermal administration of fluoxetine at reduced skin irritation levels wherein fluoxetine, preferably provided as fluoxetine acetate, is coadministered with a corticosteroid such as hydrocortisone. Also disclosed are drug delivery devices containing the fluoxetine or fluoxetine and enhancer composition and methods for the transdermal administration of the fluoxetine and fluoxetine/enhancer composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 24 USPATFULL on STN

ACCESSION NUMBER: 2003:158996 USPATFULL
TITLE: Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
INVENTOR(S): Berry, Stephen A., Hollister, CA, UNITED STATES
Ferreira, Pamela J., Redwood City, CA, UNITED STATES
Dehnad, Houdin, El Granada, CA, UNITED STATES
Muchnik, Anna, Belmont, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003108609	A1	20030612
APPLICATION INFO.:	US 2002-319277	A1	20021212 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-497422, filed on 3 Feb 2000, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-119170P	19990208 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ALZA CORPORATION, P O BOX 7210, INTELLECTUAL PROPERTY DEPARTMENT, MOUNTAIN VIEW, CA, 940397210	
NUMBER OF CLAIMS:	38	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	948	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to stable non-aqueous single phase viscous vehicles and to formulations utilizing such vehicles. The formulations comprise at least one beneficial agent uniformly suspended in the vehicle. The formulation is capable of being stored at temperatures ranging from cold to body temperature for long periods of time. The formulations are capable of being uniformly delivered from drug delivery systems at an exit shear rate of between about 1 to 1+10.sup.-7 reciprocal second.

blessing

09/497,422

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 24 USPATFULL on STN

ACCESSION NUMBER: 2003:119638 USPATFULL
TITLE: Titanium dioxide particles
INVENTOR(S): Chopin, Thierry, Saint-Leu-la-Forêt, FRANCE
Dupuis, Dominique, Deuil-la-Barre, FRANCE
Willemin, Claudie, Paris, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003082122	A1	20030501
	US 6740312	B2	20040525
APPLICATION INFO.:	US 2002-172499	A1	20020617 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-117935, filed on 13 Oct 1998, ABANDONED A 371 of International Ser. No. WO 1997-FR266, filed on 12 Feb 1997, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1996-1850	19960215
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Norman H. Stepno, BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box 1404, Alexandria, VA, 22313-1404	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1059	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Anatase titanium dioxide particles no larger than 100 nm and coated with a layer of a metal oxide, hydroxide or oxohydroxide, said particles having a BET specific surface area of at least 70 m²/g and a density of around 2.2. A method for preparing said particles, and the use thereof as an anti-UV agent, in particular for preparing formulations for cosmetics, varnishes, paints and plastics, are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 24 USPATFULL on STN

ACCESSION NUMBER: 2003:40433 USPATFULL
TITLE: Sertraline salts and sustained-release dosage forms of sertraline
INVENTOR(S): Am Ende, Mary Tanya, Griswold, CT, United States
Curatolo, William John, Niantic, CT, United States
Friedman, Hylar Lewis, Brattleboro, VT, United States
Friesen, Dwayne Thomas, Bend, OR, United States
Herbig, Scott Max, East Lyme, CT, United States
Shankar, Ravi Mysore, Groton, CT, United States
West, James Blair, Bend, OR, United States
PATENT ASSIGNEE(S): Pfizer Inc., New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6517866	B1	20030211
	WO 9901121		19990114
APPLICATION INFO.:	US 1999-380897		19990907 (9)
	WO 1998-IB934		19980615

blessing

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-51498P	19970701 (60)
	US 1997-51420P	19970701 (60)
	US 1997-51414P	19970701 (60)
	US 1997-51402P	19970701 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Spear, James M.	
LEGAL REPRESENTATIVE:	Richardson, Peter C., Benson, Gregg C., O'Gorman, Carmella A.	
NUMBER OF CLAIMS:	116	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 6 Drawing Page(s)	
LINE COUNT:	5178	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Sustained release dosage forms of sertraline which release sertraline at a rate between 1 mgA/hr and 40 mgA/hr. The dosage forms may exhibit an initial delay period during which sertraline is released at a rate less than 1 mgA/hr.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 24 USPATFULL on STN

ACCESSION NUMBER: 2003:26372 USPATFULL

TITLE: Formulations for the administration of fluoxetine

INVENTOR(S): Gale, Robert M., Los Altos, CA, United States
 Nelson, Melinda K., Sunnyvale, CA, United States
 Cormier, Michel J. N., Mountain View, CA, United States
 Gupta, Suneel K., Sunnyvale, CA, United States
 Campbell, Patricia S., Palo Alto, CA, United States

PATENT ASSIGNEE(S): Alza Corporation, Mountain View, CA, United States
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6512010	B1	20030128
APPLICATION INFO.:	US 1997-892118		19970714 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-21727P	19960715 (60)
	US 1997-38425P	19970219 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Dees, Jose' G.	
LEGAL REPRESENTATIVE:	Date, Vandana	
NUMBER OF CLAIMS:	34	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Figure(s); 7 Drawing Page(s)	
LINE COUNT:	1244	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Composition of matter for application to a body surface or membrane to administer fluoxetine by permeation through the body surface or membrane, the composition comprising fluoxetine to be administered, at a therapeutically effective rate, alone or in combination with a permeation enhancer or mixture. A preferred embodiment is directed to the transdermal administration of fluoxetine at reduced skin irritation

09/497,422

levels wherein fluoxetine, preferably provided as fluoxetine acetate, is coadministered with a corticosteroid such as hydrocortisone. Also disclosed are drug delivery devices containing the fluoxetine or fluoxetine and enhancer composition and methods for the transdermal administration of the fluoxetine and fluoxetine/enhancer composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 10 OF 24 USPATFULL on STN

ACCESSION NUMBER: 2002:314414 USPATFULL
TITLE: Methods of delivery of cetyl myristoleate
INVENTOR(S): Lord, Gary, Sparks, NV, UNITED STATES
Lytle, Carol, Reno, NV, UNITED STATES
PATENT ASSIGNEE(S): CG and Associates, Sparks, NV (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002176887	A1	20021128
APPLICATION INFO.:	US 2002-189579	A1	20020708 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-299903, filed on 28 Apr 1999, GRANTED, Pat. No. US 6417227		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	BANNER & WITCOFF, 1001 G STREET N W, SUITE 1100, WASHINGTON, DC, 20001		
NUMBER OF CLAIMS:	27		
EXEMPLARY CLAIM:	1		
LINE COUNT:	686		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides novel and advantageous delivery devices for compositions of cetyl myristoleate. The delivery devices include transdermal delivery devices, suppositories, enteric coatings, and microencapsulation. Further provided are methods of treating diseases using the disclosed delivery devices. Diseases that can be treated with the devices include, but are not limited to, diseases associated with the inflammation of tissues, diseases associated with inflammatory conditions affecting joints, and autoimmune diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 11 OF 24 USPATFULL on STN

ACCESSION NUMBER: 2002:168256 USPATFULL
TITLE: Methods of delivery of cetyl myristoleate
INVENTOR(S): Lord, Gary R., Sparks, NV, United States
Lytle, Carol D., Reno, NV, United States
PATENT ASSIGNEE(S): CG and Associates, Sparks, NV, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6417227	B1	20020709
APPLICATION INFO.:	US 1999-299903		19990428 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Williamson, Michael A.		
LEGAL REPRESENTATIVE:	Banner & Witcoff, Ltd.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)		

blessing

LINE COUNT: 610

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides novel and advantageous delivery devices for compositions of cetyl myristoleate. The delivery devices include transdermal delivery devices, suppositories, enteric coatings, and microencapsulation. Further provided are methods of treating diseases using the disclosed delivery devices. Diseases that can be treated with the devices include, but are not limited to, diseases associated with the inflammation of tissues, diseases associated with inflammatory conditions affecting joints, and autoimmune diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 12 OF 24 USPATFULL on STN

ACCESSION NUMBER: 2002:69622 USPATFULL

TITLE: Method of making pressure sensitive adhesive matrix patches for transdermal drug delivery using hydrophilic salts of drugs and hydrophobic pressure sensitive adhesive dispersions

INVENTOR(S): Venkateshwaran, Srinivasan, Salt Lake City, UT, United States

Fikstad, David, Salt Lake City, UT, United States

Ebert, Charles D., Salt Lake City, UT, United States

PATENT ASSIGNEE(S): Watson Pharmaceuticals, Inc., Corona, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6365178	B1	20020402
APPLICATION INFO.:	US 2001-764040		20010117 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-149523, filed on 8 Sep 1998, now abandoned Continuation-in-part of Ser. No. US 1996-706624, filed on 6 Sep 1996, now patented, Pat. No. US 5985317		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Dodson, Shelley A.		
LEGAL REPRESENTATIVE:	Thorpe North & Western, Koneru, Phanesh, Tran, Paul B.		
NUMBER OF CLAIMS:	48		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	1462		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of making a pressure sensitive matrix patch for transdermal delivery of a drug is disclosed. The method includes the steps of dissolving a hydrophilic salt form of the drug in the water phase of an aqueous dispersion of a hydrophobic pressure sensitive adhesive, casting the resulting mixture as a thin film, and evaporating the water. The physical stability of the drug in the film is excellent, and crystallization of the drug is inhibited. A method of increasing the transdermal flux of an acidic drug is also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 13 OF 24 USPATFULL on STN

ACCESSION NUMBER: 2001:229232 USPATFULL

TITLE: NOVEL FORMULATIONS FOR THE TRANSDERMAL ADMINISTRATION OF ASIMADOLINE

INVENTOR(S): VAN OSDOL, WILLIAM W., MOUNTAIN VIEW, CA, United States

WATANABE, TYLER, LOS ALTOS, CA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001051181	A1	20011213
APPLICATION INFO.:	US 1998-213478	A1	19981217 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-68376P	19971222 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ALZA CORPORATION, INTELLECTUAL PROPERTY DEPT, M10-3, 1900 CHARLESTON ROAD, P.O. BOX 7210, MOUNTAIN VIEW, CA, 94039-7210	
NUMBER OF CLAIMS:	28	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	938	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Composition of matter for application to a body surface or membrane to administer asimadoline by permeation through the body surface or membrane, the composition comprising asimadoline to be administered, at a therapeutically effective rate, alone or in combination with a permeation enhancer or mixture. Also disclosed are drug delivery devices and methods for the transdermal administration of asimadoline.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 14 OF 24 USPATFULL on STN

ACCESSION NUMBER: 2001:121092 USPATFULL

TITLE: Skin permeation enhancer compositions comprising a monoglyceride and ethyl palmitate

INVENTOR(S): Beste, Russell D., Mountain View, CA, United States
Hamlin, Richard D., Newark, CA, United States

PATENT ASSIGNEE(S): ALZA Corporation, Mountain View, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6267984	B1	20010731
APPLICATION INFO.:	US 1998-213835		19981217 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-68411P	19971222 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Dodson, Shelley A.	
LEGAL REPRESENTATIVE:	Date, Vandana, Stone, Steven	
NUMBER OF CLAIMS:	36	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	978	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions, devices, and methods for transdermal administration of a drug are disclosed using a novel permeation enhancer mixture comprising a monoglyceride and ethyl palmitate. The monoglyceride/ethyl palmitate permeation enhancer is a potent permeation enhancer and provides stable

09/497,422

systems which are more readily characterized. Additionally, ethyl palmitate cosolvent systems are more readily processed at manufacturing conditions thus providing further advantages over other cosolvents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 15 OF 24 USPATFULL on STN

ACCESSION NUMBER: 2001:40032 USPATFULL

TITLE: Reduction of skin reactions caused by transdermal drug delivery

INVENTOR(S): Cormier, Michel J. N., Mountain View, CA, United States
Daddona, Peter E., Menlo Park, CA, United States
Johnson, Juanita A., Belmont, CA, United StatesPATENT ASSIGNEE(S): ALZA Corporation, Mountain View, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6203817	B1	20010320
APPLICATION INFO.:	US 1998-92606		19980605 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-892118, filed on 14 Jul 1997		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-38425P	19970219 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Clardy, S. Mark	
ASSISTANT EXAMINER:	Shelborne, Kathryn E.	
LEGAL REPRESENTATIVE:	Bates, Owen J., Stone, Steven F., Date, Vandana	
NUMBER OF CLAIMS:	27	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Figure(s); 10 Drawing Page(s)	
LINE COUNT:	1076	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Transdermal compositions, devices, and methods for the administration of a drug at reduced skin irritation levels are disclosed. More particularly, this invention relates to novel methods, compositions, and devices for the reduction or elimination of irritation or sensitization caused by an irritating or sensitizing drug when it is delivered transdermally. According to a preferred embodiment, transdermal administration of a drug salt of a non-zwitterionic drug is disclosed wherein the drug salt comprises a combination of surface activity and a low octanol-water partition coefficient. Such drug salts have been found to reduce irritation or sensitization to the drug being delivered while achieving therapeutically effective transdermal fluxes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 16 OF 24 USPATFULL on STN

ACCESSION NUMBER: 2001:21885 USPATFULL

TITLE: Titanium dioxide particles, method for their preparation and their use in cosmetics, varnish and surface coating

INVENTOR(S): Chopin, Thierry, Saint-Leu la Foret, France
Dupuis, Dominique, Deuil-la-Barre, France
Pacaud, Bernard, Kobe, Japan

PATENT ASSIGNEE(S): Rhodia Chimie, Courbevoie Cedex, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6187438	B1	20010213

09/497,422

APPLICATION INFO.: WO 9801392 19980115
US 1999-214624 19990623 (9)
WO 1997-FR1208 19970704
19990623 PCT 371 date
19990623 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1996-8460	19960708
	FR 1996-11781	19960927
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Le, H. Thi	
LEGAL REPRESENTATIVE:	Burns, Doane, Swecker & Mathis, L.L.P.	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1346	

AB The invention concerns titanium dioxide particles coated at least partially: with a first layer of at least a cerium and/or iron compound, and a second layer of at least a metal oxide, hydroxide or oxohydroxide, the said particles having a BET specific surface area of at least 70 m.sup.2 /g and a density of 2.5. The invention also concerns a method for preparing these particles and their use as anti-UV agent.

L5 ANSWER 17 OF 24 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:553390 CAPLUS
DOCUMENT NUMBER: 133:155452
TITLE: Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
INVENTOR(S): Berry, Stephen A.; Fereira, Pamela J.; Dehnad, Houdin; Muchnik, Anna
PATENT ASSIGNEE(S): Alza Corporation, USA
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000045790	A2	20000810	WO 2000-US2772	20000202
WO 2000045790	A3	20001207		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1152749	A2	20011114	EP 2000-913350	20000202
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002536315	T2	20021029	JP 2000-596910	20000202
NZ 513441	A	20040130	NZ 2000-513441	20000202
AU 775904	B2	20040819	AU 2000-34816	20000202

blessing

09/497,422

ZA 2001006443	A	20020806	ZA 2001-6443	20010806
NO 2001003861	A	20010920	NO 2001-3861	20010808
US 2003108609	A1	20030612	US 2002-319277	20021212
PRIORITY APPLN. INFO.:			US 1999-119170P	P 19990208
			WO 2000-US2772	W 20000202
			US 2000-497422	B1 20000203

AB This invention relates to stable non-aqueous single phase viscous vehicles and to formulations utilizing such vehicles. The formulations comprise at least one beneficial agent uniformly suspended in the vehicle containing solvents, surfactants, and polymers. The formulation is capable of being stored at temps. ranging from cold to body temperature for long periods of time.

The formulations are capable of being uniformly delivered from drug delivery systems at an exit shear rate of between about 1 to 1×10^7 reciprocal second. A vehicle was prepared by dissolving **glycerol monolaurate** in **lauryl lactate** and blending PVP into the mixture. Lyophilized growth hormone reconstituted in deionized water was diafiltrated and spray-dried. The spray-dried powder was suspended in the above vehicle.

L5 ANSWER 18 OF 24 USPATFULL on STN

ACCESSION NUMBER: 1999:166619 USPATFULL
TITLE: Permeation enhances for transdermal drug delivery compositions, devices and methods
INVENTOR(S): Lee, Eun Soo, Redwood City, CA, United States
Yum, Su II, Los Altos, CA, United States
PATENT ASSIGNEE(S): ALZA Corporation, Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6004578		19991221
APPLICATION INFO.:	US 1997-956379		19971023 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-30424P	19961024 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Clardy, S. Mark	
ASSISTANT EXAMINER:	Williamson, Michael A.	
LEGAL REPRESENTATIVE:	Rafa, Michael J., Stone, Steven F.	
NUMBER OF CLAIMS:	34	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Figure(s); 15 Drawing Page(s)	
LINE COUNT:	851	

AB The present invention is directed to the transdermal administration of at least one drug together with a suitable amount of a permeation enhancer comprising monoalkyl ethers of polyethyleneglycol and their alkyl or aryl carboxylic acid esters and carboxymethyl ethers. The invention includes a transdermal drug delivery device comprising a matrix adapted to be placed in drug- and- permeation enhancer-transmitting relation with a skin site. The matrix contains sufficient amounts of the permeation enhancer and drug, in combination, to continuously administer drug to the systemic circulation of a patient at a therapeutically effective rate. The invention is also directed to compositions and methods for transdermal administration of at least one drug together with a permeation enhancer of this invention, alone or in combination with other enhancers.

blessing

L5 ANSWER 19 OF 24 USPATFULL on STN

ACCESSION NUMBER: 1999:109990 USPATFULL

TITLE: Fatty acid esters of lactic acid salts as permeation enhancers

INVENTOR(S): Venkateshwaran, Srinivasan, Salt Lake City, UT, United States

Fikstad, David, Salt Lake City, UT, United States

Patel, Sonal R., Sandy, UT, United States

PATENT ASSIGNEE(S): TheraTech, Inc., Salt Lake City, UT, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5952000		19990914
APPLICATION INFO.:	US 1997-959946		19971029 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-741071, filed on 30 Oct 1996, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Brouillette, D. Gabrielle		
LEGAL REPRESENTATIVE:	Thorpe, North & Western, L.L.P.		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1112		

AB A transdermal drug delivery system which enhances the delivery of the drug comprises a composition containing, as an enhancer, one or more C.sub.6 to C.sub.22 fatty acid esters of a lactic acid salt. These compositions are made up of a safe and effective amount of an active pharmaceutical permeant contained in a penetration-enhancing vehicle comprising, 0.25 to 50% w. of the fatty acid ester of a lactic acid salt enhancer in a suitable pressure sensitive adhesive carrier vehicle formed from and aqueous emulsion based pressure sensitive adhesive.

L5 ANSWER 20 OF 24 USPATFULL on STN

ACCESSION NUMBER: 1999:85017 USPATFULL

TITLE: Crystalline form of estradiol and pharmaceutical formulations comprising same

INVENTOR(S): Farinas, Kathleen C., San Carlos, CA, United States

Jayalakshmi, Yalia, Palo Alto, CA, United States

Lee, Susanne M., Albany, NY, United States

Soni, Pravin L., Sunnyvale, CA, United States

PATENT ASSIGNEE(S): Cygnus Inc., Redwood City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5928666		19990727
APPLICATION INFO.:	US 1997-968769		19971110 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-30524P	19961112 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Webman, Edward J.	
LEGAL REPRESENTATIVE:	Horne, Angela P., McClung, Barbara G.	

09/497,422

NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 866

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to a stable crystalline form of estradiol suitable for incorporation into pharmaceutical formulations. The invention further provides methods of preparing said crystalline form of estradiol. The invention further provides pharmaceutical formulations comprising said crystalline form of estradiol. The invention further provides a method of treatment of an individual in need of such administration by the transdermal administration of estradiol from a polymeric matrix comprising the crystal structure of estradiol of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 21 OF 24 USPATFULL on STN

ACCESSION NUMBER: 1999:67029 USPATFULL
TITLE: Fatty acid esters of glycolic acid and its salts
INVENTOR(S): Venkateshwaran, Srinivasan, Salt Lake City, UT, United States
Fikstad, David, Salt Lake City, UT, United States
Patel, Sonal R., Sandy, UT, United States
PATENT ASSIGNEE(S): TheraTech, Inc., Salt Lake City, UT, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5912009		19990615
APPLICATION INFO.:	US 1997-959944		19971029 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-741071, filed on 30 Oct 1996, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Page, Thurman K.		
ASSISTANT EXAMINER:	Channavajjala, Lakshmi		
LEGAL REPRESENTATIVE:	Thorpe, North & Western		
NUMBER OF CLAIMS:	40		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1167		

AB A transdermal drug delivery system which enhances the delivery of the drug comprises a composition containing, as an enhancer, one or more C.sub.6 to C.sub.22 fatty acid esters of glycolic acid and its salts. These compositions are made up of a safe and effective amount of an active pharmaceutical permeant contained in a penetration-enhancing vehicle comprising, 0.25 to 50% w. of the fatty acid glycolic acid ester enhancer in a suitable carrier vehicle. These fatty acid glycolic acid ester enhancers may be used in various carrier vehicles to enhance the transdermal delivery of active permeants in either free form or used in an occlusive device, particularly in a transdermal patch in matrix or reservoir form. When used in matrix patch form, the fatty acid glycolic acid ester enhancers and permeants are incorporated into a biocompatible adhesive. When used in a reservoir type patch, the permeant and fatty acid glycolic acid ester enhancers are incorporated into a carrier fluid of controlled viscosity such as a gel or ointment preferably containing a lower alkanol and water. In free form, the enhancer and permeant may be incorporated into an ointment, lotion, cream, or similar formulation.

blessing

09/497,422

L5 ANSWER 22 OF 24 USPATFULL on STN

ACCESSION NUMBER: 1999:61017 USPATFULL
TITLE: Supersaturated transdermal drug delivery systems, and
methods for manufacturing the same
INVENTOR(S): Farinas, Kathleen C., Belmont, CA, United States
Miller, Chad M., Durham, NC, United States
Soni, Pravin L., Sunnyvale, CA, United States
PATENT ASSIGNEE(S): Cygnus, Inc., Redwood City, CA, United States (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5906830		19990525
APPLICATION INFO.:	US 1996-708389		19960904 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-525867, filed on 8 Sep 1995, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Page, Thurman K.		
ASSISTANT EXAMINER:	Shelborne, Kathryne E.		
LEGAL REPRESENTATIVE:	McClung, Barbara G.Bozicevic & Reed, LLP.		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 6 Drawing Page(s)		
LINE COUNT:	807		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods are provided for manufacturing transdermal drug delivery systems containing supersaturated drug reservoirs, such that higher drug fluxes are obtained. The methods involve heating the drug reservoir components to a predetermined temperature. Generally, this temperature is higher than the depressed melting temperature of the polymer-drug admixture which will serve as the drug reservoir. In an alternative embodiment, wherein heat treatment of the reservoir components results in a system having two liquid phases, the predetermined temperature is calculated so as to be higher than the melting temperature of the pure drug. Drug reservoirs and novel transdermal delivery systems prepared using the disclosed techniques are provided as well.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 23 OF 24 USPATFULL on STN

ACCESSION NUMBER: 1998:118850 USPATFULL
TITLE: Cosmetic composition
INVENTOR(S): Lyle, Ian Gardner, Flintshire, United Kingdom
PATENT ASSIGNEE(S): Lever Brothers Company, Division of Conopco, Inc., New
York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5814323		19980929
APPLICATION INFO.:	US 7209991		19961015 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 9521125	19951016
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Page, Thurman K.	

blissing

09/497,422

ASSISTANT EXAMINER: Faulkner, D.
LEGAL REPRESENTATIVE: Koatz, Ronald A.
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
LINE COUNT: 494

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for reversibly applying a cosmetic composition to the skin or comprising: a) contacting the skin or hair with the cosmetic composition, the composition comprising at least one amphiphilic material which is capable of forming a water-insoluble liquid crystal phase of greater than one-dimensional periodicity and a cosmetic agent and b) when desired, removing the cosmetic composition by applying to the skin or hair a cleansing composition comprising a surface active agent and a hydrotrope capable of destroying the liquid crystal phase formed in a step a). An advantage of such a system is that the cosmetic agent is strongly adhered to the skin or hair when applied and can be effectively removed when desired.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 24 OF 24 USPATFULL on STN

ACCESSION NUMBER: 1998:150486 USPATFULL

TITLE: Skin permeation enhancer compositions comprising **glycerol monolaurate** and lauryl acetate

INVENTOR(S): Burkoth, Terry L., Oxford, England
Taskovich, Lina T., Palo Alto, CA, United States
Beste, Russell D., Mountain View, CA, United States
Gale, Robert M., Los Altos, CA, United States
Lee, Eun Soo, Redwood City, CA, United States
Hamlin, Richard D., Newark, CA, United States
Yum, Su LL, Los Altos, CA, United States
PATENT ASSIGNEE(S): ALZA Corporation, Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5843468		19981201
APPLICATION INFO.:	US 1996-644922		19960513 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-481549, filed on 7 Jun 1995, now patented, Pat. No. US 5785991		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Brouillette, D. Gabrielle		
LEGAL REPRESENTATIVE:	Rafa, Michael J., Stone, Steve F.		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 6 Drawing Page(s)		
LINE COUNT:	864		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions, devices, and methods for transdermal administration of an active agent are disclosed using a novel dual permeation enhancer mixture comprising lauryl acetate and a monoglyceride, preferably **glycerol monolaurate**. The dual permeation enhancer mixture comprising lauryl acetate is a potent permeation enhancer and provides stable systems which are more readily characterized.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

blessing